期刊文献+

ROMA与TSGF联合检测在早期卵巢上皮癌风险评估中的应用价值 被引量:2

Clinical value of combined detection of ROMA index and TSGF levels in the risk assessment of early epithelial ovarian cancer
暂未订购
导出
摘要 目的探讨卵巢上皮癌风险预测模型(ROMA)与肿瘤特异性生长因子(TSGF)联合检测在卵巢上皮癌风险评估中的应用价值。方法采用雅培i2000化学发光仪(微粒子免疫法)检测85例卵巢上皮癌患者(卵巢癌组,Ⅰ期46例、Ⅱ期39例),88例卵巢良性肿瘤患者(良性肿瘤组),81例健康女性体检人员(健康对照组)血清人附睾蛋白4(HE4)与糖类抗原CA125Ⅱ(CA125Ⅱ)水平,结合女性绝经情况计算出ROMA值;同时用日立7600-120全自动生化分析仪(速率法)检测其血清TSGF水平,并对单项及组合检测诊断早期卵巢癌的敏感性、特异性、阳性预测值、阴性预测值进行比较,探讨其联合诊断的效能。结果卵巢癌患者组血清中CA125Ⅱ、HE4、TSGF水平及ROMA值均明显高于良性肿瘤组及健康对照组,差异有统计学意义(P<0.05)。ROMA及TSGF联合检测对卵巢癌诊断的敏感性为89.4%,特异性为98.9%,阳性预测值98.7%,阴性预测值90.6%,与单项检测卵巢癌敏感性和特异性相比,差异有统计学意义(P<0.05)。结论 ROMA联合TSGF检测对于早期卵巢上皮癌风险评估具有很高的临床应用价值,适用于临床首诊患者及健康体检女性的卵巢上皮癌早期风险评估。 Objective To investigate the clinical value of combined detection of ROMA index and the tumor specific growth factor(TSGF)levels in the risk assessment of early epithelial ovarian cancer patients.Methods Serum levels of HE4 and CA125Ⅱwere detected using Abbott i2000 chemiluminescence apparatus in 85 patients with ovarian cancer,88 patients with ovarian benign disease and 81 healthy controls,the ROMA index were calculated by ovarian cancer risk assessment software in combination with menopausal status;the serum levels were detected using the Hitachi 7600-120 automatic biochemical analyzer.The diagnostic values of the tumor markers were analyzed by sensitivities,specificities,positive predictive value and negative predictive value.ResultsThe ROMA index and CA125Ⅱ,HE4,TSGF levels in the ovarian cancer group were significantly higher than those in ovarian benign disease and healthy groups,the differences were statistically significant(P〈0.05).The sensitivity speficity,positive predictive value and negative predictive value of combined detection of ROMA index and TSGF levels were 89.4%,98.9 %,98.7% and90.6%.respectively,the differences were statistically significant(P〈0.05).Conclusion Combined detection of ROMA risk prediction model with TSGF levels has a high clinical value for evaluating the risk of early ovarian epithelial carcinoma,and it is probably suitable for the risk assessment of early epithelial ovarian cancer for patients at first visit and healthy women.
出处 《国际检验医学杂志》 CAS 2016年第10期1327-1329,共3页 International Journal of Laboratory Medicine
关键词 卵巢上皮癌 风险预测模型 肿瘤特异性生长因子 风险评估 联合检测 epithelial ovarian carcinoma ROMA TSGF risk assessment joint detection
  • 相关文献

参考文献10

二级参考文献96

  • 1焦彦华,王秀艳,刘叶廷.血清CA125、CA72-4、CA199单项检测及联合检测对诊断卵巢癌的临床价值[J].现代养生,2013,0(24):72-72. 被引量:2
  • 2刘伟,李苏宜.卵巢癌化疗新进展[J].肿瘤基础与临床,2006,19(6):526-528. 被引量:19
  • 3Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem[J]. Best Pract Res Clin Obstet Gynaecol,2006,20 ( 2 ) : 207-225.
  • 4Badgwell D, Bast RC Jr. Early detection of ovarian cancer [ J ]. Dis Markers, 2007,23(5-6) :397-410.
  • 5Cragun JM. Screening for ovarian cancer [ J ]. Cancer Control, 2011,18( 1 ) :16-21.
  • 6Myers ER,. Bastian LA, Havrilesky LJ. Management of adnexal mass[ J ]. Evid Rep Technol Assess ( Full Rep),2006, (130) : 1-145.
  • 7Sturgeon CM, Duffy MJ, Walker G. The National Institute for Health and Clinical Excellence (NICE) guidelines for early detection of ovarian cancer: the pivotal role of the clinical laboratory [ J ]. Ann Clin Biochem,2011,48 ( Pt 4) :295-299.
  • 8Sjsvall K, Nilsson B, Einhorn N. The significance of serum CA 125 elevation in malignant and nonmalignant diseases[J]. Gynecol Oncol,2002,85( 1 ) :175-178.
  • 9Skates SJ, Horick N, Yu Y. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions [ J ]. J Clin Oncol, 2004,22(20):4059-4066.
  • 10Dorigo O, Berek JS. Personalizing CA125 levels for ovarian cancer screening[J]. Cancer Prev Res (Phila), 2011,4 ( 9 ) : 1356- 1359.

共引文献75

同被引文献20

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部